Catalyst Pharmaceuticals, Inc. (CPRX) Projected Future Earnings
The estimated volume of future profits for Catalyst Pharmaceuticals (CPRX) demonstrates confident growth, supported by an expansion strategy involving the acquisition of new molecules and the monetization of Firdapse. High margins driven by the global scaling of orphan drugs and FDA legal protection against generics ensure the stability of the model. Consequently, 0.28 becomes the new value of the indicator, confirming the development potential of the neurotherapy ecosystem.
Comprehensive metric breakdowns and analytics for Catalyst Pharmaceuticals (CPRX)
- share price and consensus valuation forecast:
- market capitalization details:
- book capitalization indicators:
- debt and liquidity details:
Debt to Equity Catalyst Pharmaceuticals|CPRX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Catalyst Pharma|CPRX - Company Cumulative Debt|Debt to Book Capitalization Ratio Catalyst Corp|CPRX - Long-Term Debt Volume|Company Current Liabilities Catalyst Pharmaceuticals|Quick Liquidity Indicator catalystpharma.com
- earnings and market ratios statistics:
CPRX - Final Profit|Expected Profit Catalyst Pharmaceuticals|CPRX - Market Cap to Net Income|Forward P/E Multiple Catalyst Pharmaceuticals Inc|CPRX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Catalyst Pharmaceuticals, Inc.|CPRX - Operating profit EBITDA|Earnings per share for the last twelve months Catalyst Pharmaceuticals|CPRX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months catalystpharma.com|CPRX - Net earnings per share growth this year|Earnings growth forecast for next year Catalyst Pharmaceuticals
- sales volume and revenue information:
Fundamental company analysis:CPRX, Catalyst Pharma
The monopoly status of Catalyst Pharmaceuticals (CPRX) in treating rare neurological pathologies and its expansion through the acquisition of new molecules drive its cash flow dynamics. This project-level financial result compares current demand with the actual supply of assets, filtering out speculative noise from the fundamental net profit trend, which allows investors to identify a cyclical phase reversal and avoid freezing capital at the peak of the momentum.
Competitor analysis
BIIB (Biogen) - Projected Future Earnings|Net Profit Forecast NBIX (Neurocrine Biosciences, Inc.)|Projected Future Earnings RGC|Axsome Corp - Net Profit Forecast|Projected Future Earnings ACAD (ACADIA Corp)|XENE: Net Profit Forecast|Viking Therapeutics Inc - Projected Future Earnings|Expected Net Profit Supernus Pharmaceuticals, Inc.|Denali Therapeutics Inc (DNLI) - Expected Profit|Expected Net Profit Harmony Corp (HRMY)|Future Profit BHVN|Net Profit Forecast AMLX (Amylyx Pharmaceuticals, Inc.)|Future Profit TRVI (Trevi Therapeutics)|PRAX (Praxis Precision Medicines Inc) - Expected Net Income|Expected Profit Anavex Corp AVXL|CeriBell, Inc. - Expected Profit|PRTA: Future Profit|Company Profit Forecast Alector ALEC|Annexon Inc. (ANNX) - Expected Profit|Omeros Corp. - Expected Net Income|NGNE (Neurogene Therapeutics) - Projected Future Earnings|Future Profit AC Immune Corp (ACIU)|Expected Profit Voyager Therapeutics (VYGR)|NMRA (Neumora Therapeutics) - Expected Net Income|Expected Profit Scilex Holding Co. SCLX|Expected Net Income TVGN|ACOG - Expected Profit|Expected Net Income CGTX (Cognition Therapeutics, Inc.)|IKT: Projected Future Earnings|Expected Net Profit cassavasciences.com (SAVA)|ASRT (Assertio Holdings, Inc.) - Projected Future Earnings|Future Profit coyatherapeutics.com (COYA)|Future Profit VTGN (vistagen.com)|Company Profit Forecast Ovid Rx|Projected Future Earnings ABOS (acumenpharm.com)|CRVO: Net Profit Forecast|Alterity Therapeutics Ltd. - Projected Future Earnings|Expected Net Profit clene.com|pepgen.com (PEPG) - Expected Profit|Expected Net Profit Jupiter Neurosciences, Inc. (JUNS)|Expected Profit Relmada Therapeutics|Net Profit Forecast ANVS (Annovis Bio, Inc.)|Projected Future Earnings GRCE|Company Profit Forecast Firefly Neuroscience, Inc.|Expected Profit anewmeds.com KLTO|Company Profit Forecast NeuroSense Therapeutics (NRSN)|RVPH: Future Profit|MTVA - Projected Future Earnings|NRXS (neuraxis.com) - Future Profit|Expected Net Profit Helius Medical Technologies Inc. (HSDT)|Expected Profit Passage Bio Corp|Future Profit Neuphoria Therapeutics (NEUP)|Projected Future Earnings NERV|ATHA - Expected Net Profit|Projected Future Earnings ADXN (addextherapeutics.com)|Alzamend (ALZN) - Expected Net Profit|CYCN: Future Profit|Expected Net Profit Protagenic Therapeutics Inc.|pasitheaclinics.com (KTTA) - Expected Profit|Expected Net Profit Cortigent Medical (CRGT)|ATXI (Avenue Therapeutics Inc) - Projected Future Earnings|BCLI (Brainstorm Cell Therapeutics Inc.) - Future Net Profit|Projected Future Earnings CARA|CHRO - Expected Net Profit|Eliem Therapeutics - Future Profit|Intra-Cellular (ITCI) - Expected Net Profit|LBPH - Expected Profit|MRNS - Projected Future Earnings|NKGN: Projected Future Earnings|NeuroBo Pharma (NRBO) - Projected Future Earnings|Future Profit SAGE|Net Profit Forecast SNPX (Synaptogenix, Inc.)|Expected Profit Trevena, Inc (TRVN)|VIGL (Vigil Neuroscience Inc.) - Expected Net Income|Expected Profit Anew Medical WENA|Future Net Profit CERE (Cerevel)
